

### REMARKS

By the present amendment, Applicants request entry of the sequence listing submitted herewith under 37 C.F.R. §§ 1.821-1.825. This submission, filed in accordance with 37 C.F.R. § 1.821(g), includes no new matter.

Applicants believe that the present application is now in condition for allowance which is respectfully requested. The Examiner is encouraged to call the undersigned to discuss any issues related to the prosecution of the instant application.


No additional fees are believed due for this submission beyond those fees recited in the Notification of Missing Requirements dated February 5, 2008. However, if a fee is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535 referencing Docket No. 0105US-UTL2. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.

April 1, 2008

By: \_\_\_\_\_



Steven C. Koerber  
Registration No. 54,233

AMYLIN PHARMACEUTICALS, INC.  
9360 Towne Centre Drive  
San Diego, CA 92121  
Telephone: 858-552.2200  
Facsimile: 858-552.1936